Clinical SciencePreservative-Free Low-Dose Dexamethasone for the Treatment of Chronic Ocular Surface Disease Refractory to Standard TherapyJonisch, Jonathan MD; Steiner, Anne MD; Udell, Ira J MDAuthor Information From North Shore-Long Island Jewish Health System, Department of Ophthalmology, Great Neck, NY. Received for publication March 19, 2009; revision received May 29, 2009; accepted June 20, 2009. Reprints: Ira J. Udell, MD, 600 Northern Boulevard, Suite 214, Great Neck, NY 11021 (e-mail: email@example.com). Cornea: July 2010 - Volume 29 - Issue 7 - p 723-726 doi: 10.1097/ICO.0b013e3181b765a6 Buy Metrics Abstract Purpose: To evaluate the short-term safety and efficacy of topical preservative-free dexamethasone 0.01% for the treatment of ocular surface disease and/or tearing refractory to conventional treatments. Methods: Retrospective chart review of all patients who received topical unpreserved dexamethasone 0.01% (Leiters Pharmacy, San Jose, CA). Follow-up visits were reviewed for subjective responses to the formulation and intraocular pressure. Responses were graded as significant/complete resolution of symptoms (50%-100% improvement), mild (25%-50% improvement), or no improvement. Results: Thirty-one patients received topical unpreserved dexamethasone 0.01% for the treatment of ocular surface disease. Follow up ranged from 4 to 60 months (average, 11.5 weeks). Twenty patients (65%) reported moderate or complete resolution of ocular symptoms. Seven patients (22%) had mild improvement in their symptoms. Four patients (13%) had no change in ocular symptoms. No patient in our series developed an elevation of intraocular pressure greater than 5 mm Hg above baseline intraocular pressure. No patient developed intraocular pressure greater than 22 mm Hg. Conclusions: Topical nonpreserved 0.01% dexamethasone could be an effective therapy for recalcitrant chronic ocular surface disease. Copyright © 2010 Wolters Kluwer Health, Inc. All rights reserved.